Immune Monitoring Design within the Developmental Pipeline for an Immunotherapeutic or Preventive Vaccine

Vaccinology: Principles and Practice

Volumn , Issue , 2012, Pages 417-440

  Janetzki, Sylvia ^a   Romero, Pedro ^b   Roederer, Mario ^c   Bolton, Diane L ^c   Jandus, Camilla ^b  

^a ZellNet Consulting Inc   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Bioassays; Immune monitoring; Immune responses; Immunotherapeutic and preventive vaccines; Sample logistics; T cell assays

Indexed keywords

EID: 84886022552     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118345313.ch28     Document Type: Chapter

References (114)

1. Cartwright K. From Jenner to modern smallpox vaccines. Occup Med (Lond) 2005;55(7):563.
2. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res 1991 Jan;(262):3-11.
3. Allison JP, Dranoff G (Eds). Cancer Immunotherapy ( Advances in Immunology, vol. 90). Elsevier Academic Press, San Diego, CA, 2006.
4. Fauci AS, Johnston MI, Dieffenbach CW, et al. HIV vaccine research: the way forward. Science 2008; 321(5888):530-32.
5. Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 2005;435(7042):612-19.
6. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel- T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22.
7. Schuster SJ, Neelapu SS, Gause BL, et al. (Eds). Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results. J Clin Oncol 2009;27(18s): abstr 2.
8. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23.
9. Cohen J. AIDS research. Did Merck's failed HIV vaccine cause harm? Science 2007;318(5853): 1048-9.
10. Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326(5950):285-9.
11. van der Burg SH. Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding. Expert Rev Vaccines 2008;7(1):1-5.
12. Appay V, Douek DC, Price DA. CD8+ T cell efficacy in vaccination and disease. Nat Med 2008; 14(6):623-8.
13. Rosenberg SA, Sherry RM, Morton KE, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005;175(9):6169-76.
14. Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005;115(3):739-46.
15. Verdijk P, Aarntzen EH, Punt CJ, de Vries IJ, Figdor CG. Maximizing dendritic cell migration in cancer immunotherapy. Expert Opin Biol Ther 2008;8(7): 865-74.
16. Jacobs JF, Aarntzen EH, Sibelt LA, et al. Vaccinespecific local T cell reactivity in immunotherapyassociated vitiligo in melanoma patients. Cancer Immunol Immunother 2009;58(1):145-51.
17. Slingluff CL, Jr, Yamshchikov GV, Hogan KT, et al. Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines. Ann Surg Oncol 2008;15(12):3538-49.
18. de Vries IJ, Bernsen MR, Lesterhuis WJ, et al. Immunomonitoring tumor-specific T cells in delayedtype hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005;23(24):5779-87.
19. Hoos A, Parmiani G, Hege K, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007;30(1):1-15.
20. Ezzelle J, Rodriguez-Chavez IR, Darden JM, et al. Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories. J Pharm Biomed Anal 2008; 46(1):18-29.
21. Sarzotti-Kelsoe M, Cox J, Cleland N, et al. Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials. PLoS Med 2009;6(5):e1000067.
22. Landay AL, Fleisher TA, Kuus-Reichel K, et al. Performance of Single Cell Immune Response Assays; Approved Guideline. Clinical and Laboratory Standards Institute, Wayne, PA, 2004, pp. 1-71.
23. Cox JH, Ferrari G, Kalams SA, et al. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses 2005;21(1):68-81.
24. Britten CM, Gouttefangeas C, Welters MJ, et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother 2008;57(3): 289-302.
25. Janetzki S, Panageas KS, Ben-Porat L, et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 2008;57(3):303-15.
26. Britten CM, Janetzki S, Ben-Porat L, et al. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother 2009;58(10):1701-13.
27. Boaz MJ, Hayes P, Tarragona T, et al. Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents. Clin Vaccine Immunol 2009;16(2):147-55.
28. Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A. Toward the harmonization of immune monitoring in clinical trials: quo vadis? Cancer Immunol Immunother 2008;57(3):285-8.
29. Hanekom WA, Dockrell HM, Ottenhoff TH, et al. Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med 2008;5(7):e145.
30. Tholen DW, Berte LM, Cooper WG, et al. Using Proficiency Testing to Improve the Clinical Laboratory; Approved Guideline-Second edition. Clinical and Laboratory Standards Institute, Wayne, PA, 2007, pp. 1-41.
31. Taylor CF, Field D, Sansone S-A, et al. Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project. Nat Biotechnol 2008;26(8):889-96.
32. Janetzki S, Britten CM, Kalos M, et al. "MIATA" - minimal information about T cell assays. Immunity 2009;31(4):527-8.
33. Britten CM, Janetzki S, van der Burg SH, et al. Minimal information about T cell assays (MIATA): the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother 2011;60(1):15-22.
34. Valmori D, Souleimanian NE, Tosello V, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A 2007;104(21):8947-52.
35. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009;58(5):823-30.
36. Reddy ST, van der Vlies AJ, Simeoni E, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007;25(10):1159-64.
37. Trepel M, Pasqualini R, Arap W. Chapter 4. Screening phage-display Peptide libraries for vascular targeted peptides. Methods Enzymol 2008;445:83-106.
38. Kumar P, Satchidanandam V. Ethyleneglycolbis-( beta-aminoethylether)tetraacetate as a blood anticoagulant: preservation of antigen-presenting cell function and antigen-specific proliferative response of peripheral blood mononuclear cells from stored blood. Clin Diagn Lab Immunol 2000;7(4): 578-83.
39. Nicholson JK, Green TA. Selection of anticoagulants for lymphocyte immunophenotyping. Effect of specimen age on results. J Immunol Methods 1993;165(1):31-5.
40. Shalekoff S, Page-Shipp L, Tiemessen CT. Effects of anticoagulants and temperature on expression of activation markers CD11b and HLADR on human leukocytes. Clin Diagn Lab Immunol 1998;5(5):695-702.
41. Weinberg A, Betensky RA, Zhang L, Ray G. Effect of shipment, storage, anticoagulant, and cell separation on lymphocyte proliferation assays for human immunodeficiency virus-infected patients. Clin Diagn Lab Immunol 1998;5(6):804-7.
42. Cox JH, D'Souza M, Ratto-Kim S, et al. Cellular immune assays for evaluation of vaccine efficacy in developing countries. In NR Rose, RG Hamilton, B Detrick (Eds) Manual of Clinical Laboratory Immunology. ASM Press, Washington, DC, 2005, p. 301.
43. D'Souza P Cox JH, Ferrari G, et al. Endpoint assays in HIV-1 vaccine trials: functioning in a Good Laboratory Practices environment. In U Prabhakar, M Kelley (Eds) Validation of Cell-Based Assays in the GLP Setting: A Practical Guide. John Wiley & Sons, Chichester, 2008, pp. 239-75.
44. Bull M, Lee D, Stucky J, et al. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods 2007;322(1-2): 57-69.
45. Janetzki S, Cox JH, Oden N, Ferrari G. Standardization and validation issues of the ELISPOT assay. Methods Mol Biol 2005;302:51-86.
46. Kierstead LS, Dubey S, Meyer B, et al. Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC. AIDS Res Hum Retroviruses 2007;23(1):86-92.
47. B̈oyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 1968;97: 77-89.
48. Ruitenberg JJ, Mulder CB, Maino VC, Landay AL, Ghanekar SA. VACUTAINER CPT and Ficoll density gradient separation perform equivalently in maintaining the quality and function of PBMC from HIV seropositive blood samples. BMC Immunol 2006;7:11.
49. Kreher CR, Dittrich MT, Guerkov R, Boehm BO, Tary-Lehmann M. CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J Immunol Methods 2003;278(1-2):79-93.
50. Russell ND, Hudgens MG, Ha R, Havenar-Daughton C, McElrath MJ. Moving to HIV-1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis 2003;187:226-42.
51. Smith JG, Liu X, Kaufhold RM, Clair J, Caulfield MJ. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol 2001;8(5):871-9.
52. Disis ML, Dela Rosa C, Goodell V, et al. Maximizing the retention of antigen specific lymphocyte function after cryopreservation. J Immunol Methods 2006;308(1-2):13-18.
53. Filbert H, Attig S, Bidmon N, et al. Serum-free freezing-media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. Poster presentation, CIMT Annual Meeting 2011, Mainz, Germany, abst 117. Available at: http://meeting.cimt.eu/cimtmeeting/files/dl/CIMTAbstractbook 2011.pdf. Accessed Feb 2012.
54. Weinberg A. Cryopreservation of peripheral blood mononuclear cells. In N Rose, RG Hamilton, B Detrick (Eds) Manual of Clinical Laboratory Immunology. ASM Press, Washington, DC, 2002.
55. Weinberg A, Song LY, Wilkening C, et al. Optimization and limitations of use of cryopreserved peripheral blood mononuclear cells for functional and phenotypic T-cell characterization. Clin Vaccine Immunol 2009;16(8):1176-86.
56. Smith JG, Joseph HR, Green T, et al. Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions. Clin Vaccine Immunol 2007;14(5):527-37.
57. Immatics. Immatics Company Fact Sheet, Sep 19, 2009. Available at www.immatics.net/index.php?action=download&id=421. Accessed Feb 2012.
58. Sheehy ME, McDermott AB, Furlan SN, Klenerman P, Nixon DF. A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. J Immunol Methods 2001;249(1-2): 99-110.
59. Hermans IF, Silk JD, Yang J, et al. The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J Immunol Methods 2004;285(1):25-40.
60. Betts MR, Ambrozak DR, Douek DC, et al. Analysis of total human immunodeficiency virus (HIV)- specific CD4+ and CD8+ T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001;75(24):11983-91.
61. Rubio V, Stuge TB, Singh N, et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003;9(11):1377-82.
62. Wolint P, Betts MR, Koup RA, Oxenius A. Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cells. J Exp Med 2004;199(7):925-36.
63. Dev̂evre E, Romero P, Mahnke YD. LiveCount Assay: concomitant measurement of cytolytic activity and phenotypic characterisation of CD8(+) Tcells by flow cytometry. J Immunol Methods 2006; 311(1-2):31-46.
64. Oehen S, Brduscha-Riem K. Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J Immunol 1998;161(10):5338-46.
65. Andoins C, de Fornel D, Fontet P, Dutartre P. Use of [35S]methionine-labelled rat lymphoblasts in microcytotoxic and limiting dilution assays. J Immunol Methods 1996;192(1-2):117-23.
66. Kantakamalakul W, Jaroenpool J, Pattanapanyasat K. A novel enhanced green fluorescent protein (EGFP)-K562 flow cytometric method for measuring natural killer (NK) cell cytotoxic activity. J Immunol Methods 2003;272(1-2):189-97.
67. Chung A, Rollman E, Johansson S, Kent SJ, Stratov I. The utility of ADCC responses in HIV infection. Curr HIV Res 2008;6(6):515-19.
68. Bures R, Gaitan A, Zhu T, et al. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2000;16(18):2019-35.
69. Pilgrim AK, Pantaleo G, Cohen OJ, et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997; 176(4):924-32.
70. Burns DP, Desrosiers RC. A caution on the use of SIV/HIV gag antigen detection systems in neutralization assays. AIDS Res Hum Retroviruses 1992; 8(6):1189-92.
71. Mascola JR, Burke DS. Antigen detection in neutralization assays: high levels of interfering anti-p24 antibodies in some plasma. AIDS Res Hum Retroviruses 1993;9(12):1173-4.
72. Mascola JR, Louder MK, Winter C, et al. Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of singleround infection of primary human T cells. J Virol 2002;76(10):4810-21.
73. Czerkinsky C, Andersson G, Ekre HP, et al. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gammainterferon- secreting cells. J Immunol Methods 1988; 110(1):29-36.
74. Cox JH, Ferrari G, Janetzki S. Measurement of cytokine release at the single cell level using the ELISPOT assay. Methods 2006;38(4):274-82.
75. Hesse MD, Karulin AY, Boehm BO, Lehmann PV, Tary-Lehmann M. A T cell clone's avidity is a function of its activation state. J Immunol 2001; 167(3):1353-61.
76. Bromage E, Stephens R, Hassoun L. The third dimension of ELISPOTs: quantifying antibody secretion from individual plasma cells. J Immunol Methods 2009;346(1-2):75-9.
77. Janetzki S, Price L, Britten CM, et al. Performance of serum-supplemented and serum-free media in IFNgamma Elispot assays for human T cells. Cancer Immunol Immunother 2010;59(4):609-18.
78. Boulet S, Ndongala ML, Peretz Y, et al. A dual color ELISPOT method for the simultaneous detection of IL-2 and IFN-gamma HIV-specific immune responses. J Immunol Methods 2007;320(1-2):18-29.
79. Gazagne A, Claret E, Wijdenes J, et al. A Fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines. J Immunol Methods 2003;283(1-2):91-8.
80. Rebhahn JA, Bishop C, Divekar AA, et al. Automated analysis of two- and three-color fluorescent Elispot (Fluorospot) assays for cytokine secretion. Comput Methods Programs Biomed 2008;92(1):54-65.
81. Byers AM, Tapia TM, Sassano ER, Wittman V. In vitro antibody response to tetanus in the MIMIC system is a representative measure of vaccine immunogenicity. Biologicals 2009;37(3):148-51.
82. Doria-Rose NA, Klein RM, Manion MM, et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 2009;83(1):188-99.
83. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274(5284):94-6.
84. Vollers SS, Stern LJ. Class II major histocompatibility complex tetramer staining: progress, problems, and prospects. Immunology 2008;123(3):305-13.
85. Ayyoub M, Dojcinovic D, Pignon P, et al. Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers. Proc Natl Acad Sci U S A 2010;107(16):7437-42.
86. Gagro A, Servis D, Cepika AM, et al. Type I cytokine profiles of human naive and memory B lymphocytes: a potential for memory cells to impact polarization. Immunology 2006;118(1):66-77.
87. Sun Y, Iglesias E, Samri A, et al. A systematic comparison of methods to measure HIV-1 specific CD8 T cells. J Immunol Methods 2003;272(1-2):23-34.
88. Chattopadhyay PK, Yu J, Roederer M. A livecell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nat Med 2005;11(10): 1113-17.
89. Wijdenes J, Vooijs WC, Clement C, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 1996;94(2):318-23.
90. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133(4): 1710-15.
91. Abate G, Eslick J, Newman FK, et al. Flowcytometric detection of vaccinia-induced memory effector CD4(+), CD8(+), and gamma delta TCR(+) T cells capable of antigen-specific expansion and effector functions. J Infect Dis 2005;192(8):1362-71.
92. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006;107(12): 4781-9.
93. Darrah PA, Patel DT, De Luca PM, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007;13(7):843-50.
94. Hansen SG, Vieville C, Whizin N, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009;15(3):293-9.
95. Chattopadhyay PK, Hogerkorp CM, Roederer M. A chromatic explosion: the development and future of multiparameter flow cytometry. Immunology 2008;125(4):441-9.
96. Chen R, Lowe L, Wilson JD, et al. Simultaneous quantification of six human cytokines in a single sample using microparticle-based flow cytometric technology. Clin Chem 1999;45(9):1693-4.
97. Hadrup SR, Bakker AH, Shu CJ, et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods 2009;6(7):520-26.
98. Newell EW, Klein LO, Yu W, Davis MM. Simultaneous detection of many T-cell specificities using combinatorial tetramer staining. Nat Methods 2009;6(7):497-9.
99. Maecker HT, Nolan GP, Fathman CG. New technologies for autoimmune disease monitoring. Curr Opin Endocrinol Diabetes Obes 2010;17(4):322-8.
100. Gaucher D, Therrien R, Kettaf N, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008;205(13):3119-31.
101. Shen-Orr SS, Goldberger O, Garten Y, et al. Towards a cytokine-cell interaction knowledgebase of the adaptive immune system. Pac Symp Biocomput 2009:439-50.
102. (ICH) ICoH. Guidance for Industry: Q2B Validation of Analytical Procedures: Methodology, Sep 21, 2009. Available at www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM128049.pdf. Accessed Feb 2012.
103. Findlay JW, Smith WC, Lee JW, et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal 2000;21(6):1249-73.
104. Lee JW, Devanarayan V, Barrett YC, et al. Fitfor- purpose method development and validation for successful biomarker measurement. Pharm Res 2006;23(2):312-28.
105. Horton H, Thomas EP, Stucky JA, et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 2007;323(1):39-54.
106. Mander A, Chowdhury F, Low L, Ottensmeier CH. Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines. Cancer Immunol Immunother 2009; 58(5):789-800.
107. Xu Y, Theobald V, Sung C, et al. Validation of a HLAA2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients. J Transl Med 2008;6:61.
108. Prabhakar U, Kelley M (Eds). Validation of Cell-Based Assays in the GLP Setting: A Practical Guide. John Wiley & Sons, Chichester, 2008.
109. Kalos M. An integrative paradigm to impart quality to correlative science. J Transl Med 2010;8:26.
110. Moodie Z, Price L, Gouttefangeas C, et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 2010;59(10): 1489-501.
111. Romero P, Dunbar PR, Valmori D, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998;188(9): 1641-50.
112. Romero P, Zippelius A, Kurth I, et al. Four functionally distinct populations of human effectormemory CD8+ T lymphocytes. J Immunol 2007; 178(7):4112-19.
113. Pittet MJ, Zippelius A, Speiser DE, et al. Ex vivo IFNgamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol 2001;166(12):7634-40.
114. Derre L, Bruyninx M, Baumgaertner P, et al. Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues. Proc Natl Acad Sci U S A 2008;105(39):15010-15.